Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rapid and Sustained Effect of Dupilumab on Work Productivity in Patients with Difficult-to-treat Atopic Dermatitis: Results from the Dutch BioDay Registry.
Ariëns LFM, Bakker DS, Spekhorst LS, Van der Schaft J, Thijs JL, Haeck I, Flinterman AE, Kamsteeg M, Schuttelaar MLA, De Bruin-Weller MS. Ariëns LFM, et al. Among authors: spekhorst ls. Acta Derm Venereol. 2021 Oct 19;101(10):adv00573. doi: 10.2340/00015555-3886. Acta Derm Venereol. 2021. PMID: 34396421 Free PMC article.
Two-year drug survival of dupilumab in a large cohort of difficult-to-treat adult atopic dermatitis patients compared to cyclosporine A and methotrexate: Results from the BioDay registry.
Spekhorst LS, Ariëns LFM, van der Schaft J, Bakker DS, Kamsteeg M, Oosting AJ, de Ridder I, Sloeserwij A, Romeijn GLE, de Graaf M, Haeck I, Thijs JL, Schuttelaar MLA, de Bruin-Weller MS. Spekhorst LS, et al. Allergy. 2020 Sep;75(9):2376-2379. doi: 10.1111/all.14324. Epub 2020 May 5. Allergy. 2020. PMID: 32302412 Free PMC article. No abstract available.
Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry.
Ariëns LFM, van der Schaft J, Spekhorst LS, Bakker DS, Romeijn GLE, Kouwenhoven TA, Kamsteeg M, Voorberg AN, Oosting AJ, de Ridder I, Sloeserwij A, Haeck I, Thijs JL, Schuttelaar MLA, de Bruin-Weller MS. Ariëns LFM, et al. Among authors: spekhorst ls. J Am Acad Dermatol. 2021 Apr;84(4):1000-1009. doi: 10.1016/j.jaad.2020.08.127. Epub 2020 Sep 16. J Am Acad Dermatol. 2021. PMID: 32946967
Eczema control and treatment satisfaction in atopic dermatitis patients treated with dupilumab - a cross-sectional study from the BioDay registry.
Oosterhaven JAF, Spekhorst LS, Zhang J, Voorberg AN, Romeijn GLE, Boesjes CM, de Graaf M, de Bruin-Weller MS, Schuttelaar MLA. Oosterhaven JAF, et al. Among authors: spekhorst ls. J Dermatolog Treat. 2022 Jun;33(4):1986-1989. doi: 10.1080/09546634.2021.1937485. Epub 2021 Jun 21. J Dermatolog Treat. 2022. PMID: 34151695
Dupilumab Drug Survival and Associated Predictors in Patients With Moderate to Severe Atopic Dermatitis: Long-term Results From the Daily Practice BioDay Registry.
Spekhorst LS, de Graaf M, Zuithoff NPA, van den Reek JMPA, Kamsteeg M, Boesjes CM, Romeijn GLE, Loman L, Haeck I, Oosting AJ, de Boer-Brand A, Touwslager WRH, Flinterman A, van Lynden-van Nes AMT, Gostynski AH, de Bruin-Weller MS, Schuttelaar ML. Spekhorst LS, et al. JAMA Dermatol. 2022 Sep 1;158(9):1048-1056. doi: 10.1001/jamadermatol.2022.3014. JAMA Dermatol. 2022. PMID: 35947364 Free PMC article.
Association of Serum Dupilumab Levels at 16 Weeks With Treatment Response and Adverse Effects in Patients With Atopic Dermatitis: A Prospective Clinical Cohort Study From the BioDay Registry.
Spekhorst LS, de Graaf M, Loeff F, Zuithoff NPA, Bakker D, Boesjes CM, Thijs J, Achten R, van Wijk F, Rispens T, de Bruin-Weller MS. Spekhorst LS, et al. JAMA Dermatol. 2022 Dec 1;158(12):1409-1413. doi: 10.1001/jamadermatol.2022.4639. JAMA Dermatol. 2022. PMID: 36322072 Free PMC article.
Daily Practice Experience of Baricitinib Treatment for Patients with Difficult-to-Treat Atopic Dermatitis: Results from the BioDay Registry.
Boesjes CM, Kamphuis E, Zuithoff NPA, Bakker DS, Loman L, Spekhorst LS, Haeck I, Kamsteeg M, Van Lynden-van Nes AMT, Garritsen FM, Politiek K, Oldhoff M, De Graaf M, Schuttelaar MLA, De Bruin-Weller MS. Boesjes CM, et al. Among authors: spekhorst ls. Acta Derm Venereol. 2022 Nov 24;102:adv00820. doi: 10.2340/actadv.v102.3978. Acta Derm Venereol. 2022. PMID: 36420885 Free PMC article.
17 results